JP2024536109A5 - - Google Patents
Info
- Publication number
- JP2024536109A5 JP2024536109A5 JP2024518987A JP2024518987A JP2024536109A5 JP 2024536109 A5 JP2024536109 A5 JP 2024536109A5 JP 2024518987 A JP2024518987 A JP 2024518987A JP 2024518987 A JP2024518987 A JP 2024518987A JP 2024536109 A5 JP2024536109 A5 JP 2024536109A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- adenovirus vector
- pharmaceutical composition
- oncolytic adenovirus
- vector according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20216026 | 2021-10-04 | ||
| FI20216026 | 2021-10-04 | ||
| PCT/FI2022/050662 WO2023057687A1 (en) | 2021-10-04 | 2022-10-04 | An oncolytic virus vector coding for interleukin-7 (il-7) polypeptide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024536109A JP2024536109A (ja) | 2024-10-04 |
| JP2024536109A5 true JP2024536109A5 (https=) | 2025-10-14 |
Family
ID=83690289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024518987A Pending JP2024536109A (ja) | 2021-10-04 | 2022-10-04 | インターロイキン－７（ｉｌ－７）ポリペプチドをコードする腫瘍溶解性ウイルスベクター |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240398986A1 (https=) |
| EP (1) | EP4412640A1 (https=) |
| JP (1) | JP2024536109A (https=) |
| KR (1) | KR20240073042A (https=) |
| CN (1) | CN118055776A (https=) |
| AU (1) | AU2022358966A1 (https=) |
| CA (1) | CA3233797A1 (https=) |
| WO (1) | WO2023057687A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2986311T3 (en) * | 2013-04-18 | 2019-02-25 | Tilt Biotherapeutics Oy | IMPROVED ADOPTIVE CELL THERAPY |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2986311T3 (en) | 2013-04-18 | 2019-02-25 | Tilt Biotherapeutics Oy | IMPROVED ADOPTIVE CELL THERAPY |
| AU2016232009B2 (en) | 2015-03-17 | 2021-07-15 | Tilt Biotherapeutics Oy | Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto |
| AU2019215031C1 (en) * | 2018-01-31 | 2026-02-26 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
| EP3858369A4 (en) | 2018-09-26 | 2022-07-20 | Astellas Pharma Inc. | Cancer therapy where oncolytic vaccinia virus and immune checkpoint inhibitor are used in combination, and pharmaceutical composition and combination drug used therein |
| US20220251604A1 (en) | 2019-06-14 | 2022-08-11 | Tilt Biotherapeutics Oy | Oncolytic adenovirus and checkpoint inhibitor combination therapy |
-
2022
- 2022-10-04 CN CN202280067106.6A patent/CN118055776A/zh active Pending
- 2022-10-04 KR KR1020247010765A patent/KR20240073042A/ko active Pending
- 2022-10-04 CA CA3233797A patent/CA3233797A1/en active Pending
- 2022-10-04 EP EP22789247.8A patent/EP4412640A1/en active Pending
- 2022-10-04 US US18/698,071 patent/US20240398986A1/en active Pending
- 2022-10-04 JP JP2024518987A patent/JP2024536109A/ja active Pending
- 2022-10-04 AU AU2022358966A patent/AU2022358966A1/en active Pending
- 2022-10-04 WO PCT/FI2022/050662 patent/WO2023057687A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3461491T3 (fi) | Tehostettu adoptiivinen soluterapia | |
| AU2019396761B2 (en) | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent | |
| Payne et al. | The role of chemokines in melanoma tumor growth and metastasis | |
| JP2023518295A5 (https=) | ||
| Keeley et al. | CXC chemokines in cancer angiogenesis and metastases | |
| Narazaki et al. | The role and therapeutic targeting of IL-6 in rheumatoid arthritis | |
| Le et al. | Chemokines and chemokine receptors: their manifold roles in homeostasis and disease | |
| Panse et al. | Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients | |
| Gantsev et al. | The role of inflammatory chemokines in lymphoid neoorganogenesis in breast cancer | |
| US8097250B2 (en) | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms | |
| Rainczuk et al. | The emerging role of CXC chemokines in epithelial ovarian cancer | |
| Arya et al. | Chemokines: key players in cancer | |
| Xin et al. | Exploring the role of interleukin-22 in neurological and autoimmune disorders | |
| JP2020520922A (ja) | Ｔ細胞療法を向上させるための、哺乳動物ｔ細胞の活性化により誘導可能な合成プロモーター（ｓｙｎ＋ｐｒｏ）の作製 | |
| US12016900B2 (en) | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent | |
| Lu | Structure and function of ligand CX3CL1 and its receptor CX3CR1 in cancer | |
| Kasama et al. | Clinical effects of tocilizumab on cytokines and immunological factors in patients with rheumatoid arthritis | |
| JP2023505925A (ja) | バリアント型インターロイキン－２（ｖＩＬ－２）ポリペプチドをコードする腫瘍溶解性ウイルスベクター | |
| JP2025138703A (ja) | 腫瘍溶解性アデノウイルスとチェックポイント阻害剤の併用療法 | |
| JP2024536109A5 (https=) | ||
| Özcan et al. | The role of cancer stem cells in immunotherapy for bladder cancer: An in vitro study | |
| Schröttner et al. | The role of chemokines in B cell chronic lymphocytic leukaemia: pathophysiological aspects and clinical impact | |
| Conti et al. | Chemokine‐Based Pathogenetic Mechanisms in Cancer | |
| Fujii et al. | Differential expression of chemokines, chemokine receptors, cytokines and cytokine receptors in diffuse large B cell malignant lymphoma | |
| EP3974541A1 (en) | Composition for cancer diagnosis |